Which Disease, Which Market: How a Veterinary Vaccine Manufacturer Used Market Research and Strategy Advisory to Prioritise Its Pipeline Registration Programme Across Three Candidate Markets

Veterinary vaccine registration is resource-intensive in ways that compound when attempted across multiple markets simultaneously. Each country has its own regulatory authority, its own dossier requirements, its own data generation expectations, and its own timeline for review.

The client’s business development team had ranked the three candidate markets by market size and had ranked the four disease targets by efficacy data strength, but had not combined these rankings in a way that accounted for the regulatory pathway complexity specific to each disease in each country, or for the competitive density in each disease-market combination that would determine how quickly market share could be built after registration cleared. The risk of that approach was that it would send the regulatory team to the largest market with the best efficacy data, which sounded logical, but might also be the combination where three established competitors already had strong positions and where the regulatory pathway had the most unresolved precedent questions.

The sequencing decision was also a financial one. Each registration submission had direct costs in dossier preparation, local data generation, and regulatory authority fees, and the team could only sustain a certain number of active submissions without hiring additional regulatory affairs capacity it was not budgeted for.

Key Challenges

• No market research combining disease burden, competitive vaccine landscape, and regulatory pathway complexity for all twelve disease-market combinations in a single analytical framework.
• A business development ranking that had assessed market size and efficacy data strength separately without combining them into a registration priority score.
• No assessment of competitive density in each disease-market combination that would determine how quickly post-registration market share could be built.
• A regulatory affairs team capacity constraint that made simultaneous pursuit of all twelve combinations operationally impossible without additional hiring.
• A financial constraint on active registration submissions that required a sequencing decision before the international programme could begin.
• Board expectation that the registration sequencing be grounded in a structured commercial opportunity assessment rather than a size-of-market ranking.

Veterinary vaccine registration sequencing is a portfolio investment decision, not a market size ranking exercise. The right first submission is not the one in the biggest market but the one where disease burden is meaningful, existing competition is limited, the regulatory pathway is navigable, and the registration investment can be recovered before the next submission requires the team’s full attention.